OTC Pharmaceuticals in Norway
MarketLine, March 2012, Pages: 33
Introduction
OTC Pharmaceuticals in Norway industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Norway otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
-The over-the-counter (OTC) pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.
-The Norwegian OTC pharmaceuticals market generated total revenues of $305.2 million in 2010, representing a compound annual growth rate (CAGR) of 4.3% for the period spanning 2006-2010.
-Analgesics sales proved the most lucrative for the Norwegian OTC pharmaceuticals market in 2010, generating total revenues of $64 million, equivalent to 21% of the market's overall value.
-The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.4% for the five-year period 2010-2015, which is expected to lead the market to a value of $360.3 million by the end of 2015.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Norway
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Norway
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Norway otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Norway economy
Key Questions Answered
What was the size of the Norway otc pharmaceuticals market by value in 2010?
What will be the size of the Norway otc pharmaceuticals market in 2015?
What factors are affecting the strength of competition in the Norway otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Norway's otc pharmaceuticals market?
TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 6
Market definition 6
Market analysis 6
MARKET DATA 7
Market value 7
MARKET SEGMENTATION 8
Category segmentation 8
Geography segmentation 10
Market share 11
Market distribution 12
MARKET OUTLOOK 13
Market value forecast 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
LEADING COMPANIES 20
Weifa AS 20
Johnson & Johnson 21
Novartis AG 25
MACROECONOMIC INDICATORS 28
Country Data 28
APPENDIX 30
Methodology 30
Industry associations 31
Related MarketLine research 31
LIST OF TABLES
Table 1: Norway OTC pharmaceuticals market value: $ million, 2006–10 7
Table 2: Norway OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010 8
Table 3: Norway OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 8
Table 4: Norway OTC pharmaceuticals market geography segmentation, by value, 2010 10
Table 5: Norway OTC pharmaceuticals market share: % share, by value, 2010 11
Table 6: Norway OTC pharmaceuticals market distribution: % share, by value, 2010 12
Table 7: Norway OTC pharmaceuticals market value forecast: $ million, 2010–15 13
Table 8: Weifa AS: key facts 20
Table 9: Johnson & Johnson: key facts 21
Table 10: Johnson & Johnson: key financials ($) 23
Table 11: Johnson & Johnson: key financial ratios 23
Table 12: Novartis AG: key facts 25
Table 13: Novartis AG: key financials ($) 26
Table 14: Novartis AG: key financial ratios 26
Table 15: Norway size of population (million), 2006–10 28
Table 16: Norway GDP (constant 2000 prices, $ billion), 2006–10 28
Table 17: Norway GDP (current prices, $ billion), 2006–10 28
Table 18: Norway inflation, 2006–10 29
Table 19: Norway consumer price index (absolute), 2006–10 29
Table 20: Norway exchange rate, 2006–10 29
LIST OF FIGURES
Figure 1: Norway OTC pharmaceuticals market value: $ million, 2006–10 7
Figure 2: Norway OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 9
Figure 3: Norway OTC pharmaceuticals market geography segmentation : % share, by value, 2010 10
Figure 4: Norway OTC pharmaceuticals market share: % share, by value, 2010 11
Figure 5: Norway OTC pharmaceuticals market distribution: % share, by value, 2010 12
Figure 6: Norway OTC pharmaceuticals market value forecast: $ million, 2010–15 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Norway, 2010 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Norway, 2010 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Norway, 2010 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Norway, 2010 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Norway, 2010 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Norway, 2010 19
Figure 13: Johnson & Johnson: revenues & profitability 24
Figure 14: Johnson & Johnson: assets & liabilities 24
Figure 15: Novartis AG: revenues & profitability 27
Figure 16: Novartis AG: assets & liabilities 27
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
